Evaluation of cytochrome P450 4 family as mediator of phospholipase D activation in aortic vascular smooth muscle cells.
Norepinephrine (NE) stimulates phospholipase D (PLD) activity via phospholipase A2-dependent arachidonic acid release in rabbit aortic vascular smooth muscle cells (VSMC). We have previously shown that exogenous 20-hydroxyeicosatetraenoic acid (20-HETE), an eicosanoid generated through the cytochrome P450 (CYP) 4A pathway in vivo, stimulates PLD activity. Whether endogenous CYP4-derived arachidonic acid metabolites act as intracellular mediators of NE-induced PLD activation in VSMC is not known. In rabbit aortic VSMC, prototypical hepatic/renal CYP4A inducers such as fenofibrate and Wy 14643 inhibited both basal and NE-induced PLD activity after 48 h of exposure. The level of CYP4F, and to a lesser extent CYP4A, was also decreased by these agents. The expression levels of rabbit aortic VSMC CYP4A and CYP4F isoforms were reduced by antisense oligonucleotides treatment for 48 hours as measured by RTQ-PCR or Western blotting. This reduction in CYP4A or CYP4F levels did not change NE-induced PLD activation. The corresponding CYP4A scrambled and CYP4F sense oligonucleotides did not alter CYP levels. PLD activity was increased by ~70% after 15 min of stimulation with NE, whereas lauric acid omega-hydroxylase activity, a measure of fatty acid omega-hydroxylation, was unchanged. Inhibition of omega-hydroxylation with DDMS and HET0016, selective omega-hydroxylase inhibitors, and 20-HEDE, an antagonist of 20-HETE, increased PLD activity in a concentration-dependent manner and did not alter NE-induced PLD activation. These data suggest that PLD activation by NE is independent of the CYP4A/4F enzymes in rabbit aortic VSMC.
Parmentier
Jean-Hugues
JH
Department of Pharmacology, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Lavrentyev
Eduard N
EN
Falck
John R
JR
Capdevila
Jorge H
JH
Malik
Kafait U
KU
D000577:Amides / Q000494:pharmacology; D000818:Animals; D001011:Aorta; D042926:Cytochrome P-450 CYP4A / Q000096:biosynthesis; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000502:physiology*; D000072470:Cytochrome P450 Family 4; D015536:Down-Regulation; D004789:Enzyme Activation / Q000187:drug effects; D011345:Fenofibrate / Q000494:pharmacology; D006893:Hydroxyeicosatetraenoic Acids / Q000502:physiology; D008297:Male; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D020025:Peroxisome Proliferators / Q000494:pharmacology; D010739:Phospholipase D / Q000378:metabolism*; D011743:Pyrimidines / Q000494:pharmacology; D011817:Rabbits; D013450:Sulfones / Q000494:pharmacology
D000577:Amides; D065607:Cytochrome P-450 Enzyme Inhibitors; D006893:Hydroxyeicosatetraenoic Acids; D016376:Oligonucleotides, Antisense; D020025:Peroxisome Proliferators; D011743:Pyrimidines; D013450:Sulfones; C055987:20-hydroxy-5,8,11,14-eicosatetraenoic acid; C006253:pirinixic acid; D003577:Cytochrome P-450 Enzyme System; C117975:DDMS; D006899:Mixed Function Oxygenases; C067516:arachidonic acid 18-hydroxylase; C465348:Cyp4f1 protein, rat; D000072470:Cytochrome P450 Family 4; D042926:Cytochrome P-450 CYP4A; D010739:Phospholipase D; D011345:Fenofibrate; D009638:Norepinephrine